NEW DELHI, India — The expiry of the patent on semaglutide, the key ingredient behind blockbuster drugs Wegovy and Ozempic, is set to trigger a wave of cheaper generic alternatives in India, potentially transforming access to weight-loss and diabetes treatment.
The patent lapse allows domestic pharmaceutical companies to introduce lower-cost versions of the drug, with analysts predicting prices could drop by more than half.
Investment bank Jefferies has described the moment as a potential “magic pill” turning point, estimating India’s semaglutide market could grow to $1 billion with wider adoption.
India’s generics-driven pharmaceutical industry is expected to move quickly. Analysts forecast as many as 50 branded versions could enter the market within months, echoing past trends such as the surge in alternatives following the 2022 patent expiry of sitagliptin.
Major manufacturers, including Cipla, Sun Pharma, Dr. Reddy’s Laboratories, Biocon, Zydus Lifesciences, and Mankind Pharma, are preparing to launch generics.
Currently, monthly treatment costs remain high, with Ozempic priced between 8,800 and 11,000 rupees and Wegovy costing up to 16,000 rupees. Experts expect generics to cut this to roughly 3,000–5,000 rupees, significantly expanding access.
Semaglutide belongs to a class of medicines known as GLP-1 receptor agonists, which regulate appetite and blood sugar by increasing insulin release and slowing stomach emptying. Initially developed for diabetes, these drugs have gained global popularity for their effectiveness in weight loss.
India’s growing burden of lifestyle diseases underscores the potential impact. The country has over 77 million people living with type 2 diabetes and a rapidly rising population of overweight adults, driven by urban lifestyles and dietary patterns.
Doctors say broader access could improve treatment options across specialties, from cardiology to orthopaedics, but caution against misuse. Side effects such as nausea, digestive issues, and rare complications like pancreatitis remain concerns, particularly if drugs are used without medical supervision.
Regulators have already moved to curb excessive promotion. Authorities recently warned pharmaceutical firms against direct advertising of prescription weight-loss drugs, stressing that such treatments must be used under professional guidance.
Experts also warn that falling prices could lead to overuse or misuse, especially through unregulated channels such as gyms, beauty clinics, and online pharmacies.
Still, the development reinforces India’s position as the “pharmacy of the world,” with its generics industry supplying around 20 percent of global demand.